All Stories

  1. Dapagliflozin and cardiovascular outcomes: anything else to DECLARE?

    Article • Expert Opinion on Pharmacotherapy, March 2019, Taylor & Francis

    Fabrizio De Ponti

  2. Pharmacotherapy of type 2 diabetes in patients with chronic liver disease: focus on nonalcoholic fatty liver disease

    Article • Expert Opinion on Pharmacotherapy, October 2018, Taylor & Francis

    Fabrizio De Ponti

  3. Multiple sclerosis as an adverse drug reaction: clues from the FDA Adverse Event Reporting System

    Article • Expert Opinion on Drug Safety, August 2018, Taylor & Francis

    Dr Kjetil Bjørnevik, Fabrizio De Ponti

  4. No signal of interactions between influenza vaccines and drugs used for chronic diseases: a case-by-case analysis of the vaccine adverse event reporting system and vigibase

    Article • Expert Review of Vaccines, March 2018, Taylor & Francis

    Fabrizio De Ponti

  5. Advancements in drug development for diarrhea-predominant irritable bowel syndrome

    Article • Expert Opinion on Investigational Drugs, February 2018, Taylor & Francis

    Fabrizio De Ponti, Giovanni Barbara

  6. Switching among Equivalents in Chronic Cardiovascular Therapies: ‘Real World’ Data from Italy

    Article • Basic & Clinical Pharmacology & Toxicology, August 2015, Wiley

    Fabrizio De Ponti

  7. Liver injury with novel oral anticoagulants: assessing post-marketing reports in the US Food and Drug Administration adverse event reporting system

    Article • British Journal of Clinical Pharmacology, May 2015, Wiley

    Fabrizio De Ponti

  8. Nerve Fiber Outgrowth Is Increased in the Intestinal Mucosa of Patients With Irritable Bowel Syndrome

    Article • Gastroenterology, May 2015, Elsevier

    Fabrizio De Ponti

  9. Drug-Induced Renal Damage in Preterm Neonates: State of the Art and Methods for Early Detection

    Article • Drug Safety, April 2015, Springer Science + Business Media

    Fabrizio De Ponti, Professor karel allegaert

  10. Posterior Reversible Encephalopathy Syndrome Associated With Licorice Consumption: A Case Report in a 10-Year-Old Boy

    Article • Pediatric Neurology, April 2015, Elsevier

    Fabrizio De Ponti

  11. Pro-Arrhythmic Potential of Oral Antihistamines (H1): Combining Adverse Event Reports with Drug Utilization Data across Europe

    Article • PLoS ONE, March 2015, PLOS

    Fabrizio De Ponti

  12. Comment on: “Pharmacokinetics in Patients with Chronic Liver Disease and Hepatic Safety of Incretin-Based Therapies for the Management of Type 2 Diabetes Mellitus”

    Article • Clinical Pharmacokinetics, February 2015, Springer Science + Business Media

    Fabrizio De Ponti

  13. Drug- and herb-induced liver injury: Progress, current challenges and emerging signals of post-marketing risk

    Article • World Journal of Hepatology, January 2015, Baishideng Publishing Group Co., Limited (formerly WJG Press)

    Fabrizio De Ponti

  14. Adverse cardiovascular events associated with triptans and ergotamines for treatment of migraine: Systematic review of observational studies

    Article • Cephalalgia, September 2014, SAGE Publications

    Fabrizio De Ponti

  15. Use of phytoestrogens and effects perceived by postmenopausal women: result of a questionnaire-based survey

    Article • BMC Complementary and Alternative Medicine, July 2014, Springer Science + Business Media

    Fabrizio De Ponti

  16. Pharmacological prioritisation of signals of disproportionate reporting: proposal of an algorithm and pilot evaluation

    Article • European Journal of Clinical Pharmacology, March 2014, Springer Science + Business Media

    Fabrizio De Ponti

  17. Detection of D-penicillamine in skin lesions in a case of dermal elastosis after a previous long-term treatment for Wilson's disease

    Article • Journal of the European Academy of Dermatology and Venereology, January 2014, Wiley

    Fabrizio De Ponti

  18. Lubiprostone: pharmacokinetic, pharmacodynamic, safety and regulatory aspects in the treatment of constipation-predominant irritable bowel syndrome

    Article • Expert Opinion on Drug Metabolism & Toxicology, January 2014, Informa Healthcare

    Fabrizio De Ponti

  19. Assessing liver injury associated with antimycotics: Concise literature review and clues from data mining of the FAERS database

    Article • World Journal of Hepatology, January 2014, Baishideng Publishing Group Co., Limited (formerly WJG Press)

    Fabrizio De Ponti

  20. Phytoestrogens in Postmenopause: The State of the Art from a Chemical, Pharmacological and Regulatory Perspective

    Article • Current Medicinal Chemistry, December 2013, Bentham Science Publishers

    Fabrizio De Ponti

  21. Torsadogenic Risk of Antipsychotics: Combining Adverse Event Reports with Drug Utilization Data across Europe

    Article • PLoS ONE, November 2013, PLOS

    Fabrizio De Ponti

  22. Trend in SSRI-SNRI antidepressants prescription over a 6-year period and predictors of poor adherence

    Article • European Journal of Clinical Pharmacology, August 2013, Springer Science + Business Media

    Fabrizio De Ponti

  23. Animal models of chemically induced intestinal inflammation: Predictivity and ethical issues

    Article • Pharmacology & Therapeutics, July 2013, Elsevier

    Fabrizio De Ponti

  24. Antipsychotics and Torsadogenic Risk: Signals Emerging from the US FDA Adverse Event Reporting System Database

    Article • Drug Safety, April 2013, Springer Science + Business Media

    Fabrizio De Ponti

  25. Disproportionality signal of progressive multifocal leukoencephalopathy: monoclonal antibodies versus other immunosuppressants

    Article • Pharmacoepidemiology and Drug Safety, April 2013, Wiley

    Fabrizio De Ponti

  26. Drug Development for the Irritable Bowel Syndrome: Current Challenges and Future Perspectives

    Article • Frontiers in Pharmacology, January 2013, Frontiers

    Fabrizio De Ponti

  27. Academic output from EU-funded health research projects

    Article • The Lancet, December 2012, Elsevier

    Fabrizio De Ponti

  28. Portal hypertension and liver cirrhosis in rats: effect of the β3-adrenoceptor agonist SR58611A

    Article • British Journal of Pharmacology, October 2012, Wiley

    Fabrizio De Ponti

  29. Colonic mucosal mediators from patients with irritable bowel syndrome excite enteric cholinergic motor neurons

    Article • Neurogastroenterology & Motility, September 2012, Wiley

    Fabrizio De Ponti

  30. Trends in antiarrhythmic drug use after marketing authorization of dronedarone: comparison between Emilia Romagna (Italy) and Sweden

    Article • European Journal of Clinical Pharmacology, September 2012, Springer Science + Business Media

    Fabrizio De Ponti

  31. Erratum to: Cardiovascular toxicity of anticancer-targeted therapy: emerging issues in the era of cardio-oncology

    Article • Internal and Emergency Medicine, February 2012, Springer Science + Business Media

    Fabrizio De Ponti

  32. Cardiovascular toxicity of anticancer-targeted therapy: emerging issues in the era of cardio-oncology

    Article • Internal and Emergency Medicine, December 2011, Springer Science + Business Media

    Fabrizio De Ponti

  33. The association of pancreatitis with antidiabetic drug use: gaining insight through the FDA pharmacovigilance database

    Article • Acta Diabetologica, October 2011, Springer Science + Business Media

    Fabrizio De Ponti

  34. QT interval shortening in spontaneous reports submitted to the FDA: the need for consensus

    Article • British Journal of Clinical Pharmacology, October 2011, Wiley

    Fabrizio De Ponti

  35. Excipients in medicinal products used in gastroenterology as a possible cause of side effects

    Article • Regulatory Toxicology and Pharmacology, June 2011, Elsevier

    Fabrizio De Ponti

  36. Intestinal Serotonin Release, Sensory Neuron Activation, and Abdominal Pain in Irritable Bowel Syndrome

    Article • The American Journal of Gastroenterology, March 2011, Nature

    Fabrizio De Ponti

  37. Targeting the Arrhythmogenic Substrate in Atrial Fibrillation: Focus on Structural Remodeling

    Article • Current Drug Targets, February 2011, Bentham Science Publishers

    Fabrizio De Ponti

  38. Cardiovascular events in statin recipients: impact of adherence to treatment in a 3-year record linkage study

    Article • European Journal of Clinical Pharmacology, December 2010, Springer Science + Business Media

    Fabrizio De Ponti

  39. Proinflammatory role of vasopressin through V1b receptors in hapten-induced experimental colitis in rodents: implication in IBD

    Article • AJP Gastrointestinal and Liver Physiology, September 2010, American Physiological Society

    Fabrizio De Ponti

  40. Gender- and Age-Related Differences in Muscular and Nerve-Mediated Responses in Human Colon

    Article • Digestive Diseases and Sciences, July 2010, Springer Science + Business Media

    Fabrizio De Ponti

  41. Role of drugs and devices in patients at risk of sudden cardiac death

    Article • Fundamental and Clinical Pharmacology, June 2010, Wiley

    Fabrizio De Ponti

  42. Antimicrobials and the Risk of Torsades de Pointes

    Article • Drug Safety, April 2010, Springer Science + Business Media

    Fabrizio De Ponti

  43. Anticancer drugs and cardiotoxicity: Insights and perspectives in the era of targeted therapy

    Article • Pharmacology & Therapeutics, February 2010, Elsevier

    Fabrizio De Ponti

  44. Non-peptidyl low molecular weight radical scavenger IAC attenuates DSS-induced colitis in rats

    Article • World Journal of Gastroenterology, January 2010, Baishideng Publishing Group Co., Limited (formerly WJG Press)

    Fabrizio De Ponti

  45. hERG-related drug toxicity and models for predicting hERG liability and QT prolongation

    Article • Expert Opinion on Drug Metabolism & Toxicology, July 2009, Informa Healthcare

    Fabrizio De Ponti

  46. Effects of the non-peptidyl low molecular weight radical scavenger IAC in DNBS-induced colitis in rats

    Article • European Journal of Pharmacology, July 2009, Elsevier

    Fabrizio De Ponti

  47. Drug-induced torsades de pointes: data mining of the public version of the FDA Adverse Event Reporting System (AERS)

    Article • Pharmacoepidemiology and Drug Safety, April 2009, Wiley

    Fabrizio De Ponti

  48. The β3-adrenoceptor as a therapeutic target: Current perspectives

    Article • Pharmacological Research, April 2009, Elsevier

    Fabrizio De Ponti

  49. Exposure to antibacterial agents with QT liability in 14 European countries: trends over an 8-year period

    Article • British Journal of Clinical Pharmacology, January 2009, Wiley

    Fabrizio De Ponti

  50. Protection from DNBS-induced colitis by the tachykinin NK1 receptor antagonist SR140333 in rats

    Article • European Journal of Pharmacology, January 2009, Elsevier

    Fabrizio De Ponti

  51. Strategy for a Genetic Assessment of Antipsychotic and Antidepressant- Related Proarrhythmia

    Article • Current Medicinal Chemistry, October 2008, Bentham Science Publishers

    Fabrizio De Ponti

  52. The β3-adrenoceptor agonist SR58611A ameliorates experimental colitis in rats

    Article • Neurogastroenterology & Motility, September 2008, Wiley

    Fabrizio De Ponti

  53. The hERG K+ channel: target and antitarget strategies in drug development

    Article • Pharmacological Research, March 2008, Elsevier

    Fabrizio De Ponti

  54. Adherence to chronic cardiovascular therapies: persistence over the years and dose coverage

    Article • British Journal of Clinical Pharmacology, March 2007, Wiley

    Fabrizio De Ponti

  55. Publication of a negative trial without disclosing the drug

    Article • Alimentary Pharmacology & Therapeutics, February 2007, Wiley

    Fabrizio De Ponti

  56. Serotonergic and non-serotonergic targets in the pharmacotherapy of visceral hypersensitivity

    Article • Neurogastroenterology & Motility, January 2007, Wiley

    Fabrizio De Ponti

  57. An update on the first decade of the European centralized procedure: how many innovative drugs?

    Article • British Journal of Clinical Pharmacology, November 2006, Wiley

    Fabrizio De Ponti

  58. Generic versus brand-name medicinal products: Are they really interchangeable?

    Article • Digestive and Liver Disease, August 2006, Elsevier

    Fabrizio De Ponti

  59. Enteric neuroplasticity evoked by inflammation

    Article • Autonomic Neuroscience, June 2006, Elsevier

    Fabrizio De Ponti

  60. Pharmacological and Pharmacokinetic Aspects of Functional Gastrointestinal Disorders

    Article • Gastroenterology, April 2006, Elsevier

    Fabrizio De Ponti

  61. Differential Role of Cyclooxygenase 1 and 2 Isoforms in the Modulation of Colonic Neuromuscular Function in Experimental Inflammation

    Article • Journal of Pharmacology and Experimental Therapeutics, February 2006, American Society for Pharmacology & Experimental Therapeutics (ASPET)

    Fabrizio De Ponti

  62. Gastro-intestinal problems and concomitant medication in NSAID users: additional findings from a questionnaire-based survey in Italy

    Article • European Journal of Clinical Pharmacology, January 2006, Springer Science + Business Media

    Fabrizio De Ponti

  63. 5-HT7 Receptors Modulate Peristalsis and Accommodation in the Guinea Pig Ileum

    Article • Gastroenterology, November 2005, Elsevier

    Fabrizio De Ponti

  64. Initial treatment of hypertension and adherence to therapy in general practice in Italy

    Article • European Journal of Clinical Pharmacology, August 2005, Springer Science + Business Media

    Fabrizio De Ponti

  65. Effect of muscarinic receptor blockade on canine gastric tone and compliance in vivo

    Article • Pharmacological Research, April 2005, Elsevier

    Fabrizio De Ponti

  66. Pattern of NSAID use in the Italian general population: a questionnaire-based survey

    Article • European Journal of Clinical Pharmacology, October 2004, Springer Science + Business Media

    Fabrizio De Ponti

  67. Pharmacology of serotonin: what a clinician should know

    Article • Gut, October 2004, BMJ

    Fabrizio De Ponti

  68. Antibacterial macrolides: a drug class with a complex pharmacological profile

    Article • Pharmacological Research, September 2004, Elsevier

    Fabrizio De Ponti

  69. Diagnosis and therapy of irritable bowel syndrome

    Article • Alimentary Pharmacology & Therapeutics, July 2004, Wiley

    Fabrizio De Ponti

  70. Inflammatory neuropathies of the enteric nervous system☆

    Article • Gastroenterology, June 2004, Elsevier

    Fabrizio De Ponti

  71. Colonic smooth muscle responses in patients with diverticular disease of the colon: effect of the NK2 receptor antagonist SR48968

    Article • Digestive and Liver Disease, May 2004, Elsevier

    Fabrizio De Ponti

  72. Clinical implications of enteric and central D2 receptor blockade by antidopaminergic gastrointestinal prokinetics

    Article • Alimentary Pharmacology & Therapeutics, February 2004, Wiley

    Fabrizio De Ponti

  73. QT prolongation through hERG K+ channel blockade: Current knowledge and strategies for the early prediction during drug development

    Article • Medicinal Research Reviews, January 2004, Wiley

    Fabrizio De Ponti

  74. Progress with Novel Pharmacological Strategies for Gastro-oesophageal Reflux Disease

    Article • Drugs, January 2004, Springer Science + Business Media

    Fabrizio De Ponti

  75. Triptans and gastric accommodation: pharmacological and therapeutic aspects

    Article • Digestive and Liver Disease, January 2004, Elsevier

    Fabrizio De Ponti

  76. Prescriptions of antidepressants in primary care in Italy: pattern of use after admission of selective serotonin reuptake inhibitors for reimbursement

    Article • European Journal of Clinical Pharmacology, November 2003, Springer Science + Business Media

    Fabrizio De Ponti

  77. Review of the implications of dietary tryptophan intake in patients with irritable bowel syndrome and psychiatric disorders

    Article • Digestive and Liver Disease, August 2003, Elsevier

    Fabrizio De Ponti

  78. Anti-HuD-induced neuronal apoptosis underlying paraneoplastic gut dysmotility

    Article • Gastroenterology, July 2003, Elsevier

    Fabrizio De Ponti

  79. Altered prejunctional modulation of intestinal cholinergic and noradrenergic pathways byα2-adrenoceptors in the presence of experimental colitis

    Article • British Journal of Pharmacology, May 2003, Wiley

    Fabrizio De Ponti

  80. Novel therapeutic strategies in acid-related disorders

    Article • Expert Opinion on Therapeutic Patents, May 2003, Informa Healthcare

    Fabrizio De Ponti

  81. The influence of surgery, immunosuppressive drugs, and rejection, on graft function after small bowel transplantation: a large-animal study

    Article • Transplant International, May 2003, Wiley

    Fabrizio De Ponti

  82. 5-HT4 Receptors contribute to the motor stimulating effect of levosulpiride in the guinea-pig gastrointestinal tract

    Article • Digestive and Liver Disease, April 2003, Elsevier

    Fabrizio De Ponti

  83. New Developments in the Treatment of Functional Dyspepsia

    Article • Drugs, January 2003, Springer Science + Business Media

    Fabrizio De Ponti

  84. Treatment functional GI disease: the complex pharmacology of serotonergic drugs

    Article • British Journal of Clinical Pharmacology, December 2002, Wiley

    Fabrizio De Ponti

  85. Non-antiarrhythmic drugs prolonging the QT interval:considerable use in seven countries

    Article • British Journal of Clinical Pharmacology, September 2002, Wiley

    Fabrizio De Ponti

  86. Clinical and morphofunctional features of idiopathic myenteric ganglionitis underlying severe intestinal motor dysfunction: a study of three cases

    Article • The American Journal of Gastroenterology, September 2002, Nature

    Fabrizio De Ponti

  87. Toward a Pharmacophore for Drugs Inducing the Long QT Syndrome:  Insights from a CoMFA Study of HERG K+Channel Blockers

    Article • Journal of Medicinal Chemistry, August 2002, American Chemical Society (ACS)

    Fabrizio De Ponti

  88. NONSTEROIDAL ANTI-INFLAMMATORY DRUGS AND INFLAMMATORY BOWEL DISEASE: CURRENT PERSPECTIVES

    Article • Pharmacological Research, July 2002, Elsevier

    Fabrizio De Ponti

  89. Role of tachykininergic and cholinergic pathways in modulating canine gastric tone and compliance in vivo

    Article • Pharmacological Research, April 2002, Elsevier

    Fabrizio De Ponti

  90. The cathartic colon?

    Article • Alimentary Pharmacology & Therapeutics, March 2002, Wiley

    Fabrizio De Ponti

  91. Use of anti-asthmatic drugs in Italy: analysis of prescriptions in general practice in the light of guidelines for asthma treatment

    Article • European Journal of Clinical Pharmacology, February 2002, Springer Science + Business Media

    Fabrizio De Ponti

  92. Clinical Findings and Anti-Neuronal Antibodies in Coeliac Disease with Neurological Disorders

    Article • Scandinavian Journal of Gastroenterology, January 2002, Taylor & Francis

    Fabrizio De Ponti

  93. Intestinal motor stimulation by the 5-HT4 receptor agonist ML10302: differential involvement of tachykininergic pathways in the canine small bowel and colon

    Article • Neurogastroenterology & Motility, December 2001, Wiley

    Fabrizio De Ponti

  94. The pharmacological treatment of acute colonic pseudo-obstruction

    Article • Alimentary Pharmacology & Therapeutics, November 2001, Wiley

    Fabrizio De Ponti

  95. Organising evidence on QT prolongation and occurrence of Torsades de Pointes with non-antiarrhythmic drugs: a call for consensus

    Article • European Journal of Clinical Pharmacology, June 2001, Springer Science + Business Media

    Fabrizio De Ponti

  96. Gastric motor effects of triptans: open questions and future perspectives

    Article • Pharmacological Research, March 2001, Elsevier

    Fabrizio De Ponti

  97. Correlations between functional changes and different grades of acute rejection in swine small bowel allografts

    Article • Transplantation Proceedings, September 2000, Elsevier

    Fabrizio De Ponti

  98. Review article: cardiac adverse effects of gastrointestinal prokinetics

    Article • Alimentary Pharmacology & Therapeutics, December 1999, Wiley

    Fabrizio De Ponti

  99. Modulation of enteric cholinergic neurons by hetero- and autoreceptors: Cooperation among inhibitory inputs

    Article • Life Sciences, July 1999, Elsevier

    Fabrizio De Ponti

  100. ATYPICAL β-ADRENOCEPTORS MEDIATING RELAXATION IN THE HUMAN COLON: FUNCTIONAL EVIDENCE FOR β3-RATHER THAN β4-ADRENOCEPTORS

    Article • Pharmacological Research, May 1999, Elsevier

    Fabrizio De Ponti

  101. Functional Gut Disorders

    Article • Pharmacology & Therapeutics, October 1998, Elsevier

    Fabrizio De Ponti

  102. Peripheral Benzodiazepine Receptor Expression on Leukocytes and Neutrophil Function during Anticonvulsant Monotherapy

    Article • Pharmacology, September 1998, Karger Publishers

    Fabrizio De Ponti

  103. Effects of Carbamazepine on Human PMN Function: Possible Role of Peripheral Benzodiazepine Receptors

    Article • Annals of the New York Academy of Sciences, December 1997, Wiley

    Fabrizio De Ponti

  104. Absence of histamine H3-receptors in the rabbit colon: Species difference

    Article • General Pharmacology The Vascular System, August 1997, Elsevier

    Fabrizio De Ponti

  105. Acetylcholine detection by a modified HPLC-ED method improves the assessment of cholinergic function in the myenteric plexus of the guinea-pig colon

    Article • Neuroscience Letters, August 1997, Elsevier

    Fabrizio De Ponti

  106. Small bowel myoelectrical activity after transplantation in pigs: Motility versus ACR score

    Article • Transplantation Proceedings, May 1997, Elsevier

    Fabrizio De Ponti

  107. Morphological and functional changes in small-bowel allografts of pigs under combined tacrolimus and mycophenolate mofetil immunosuppression

    Article • Transplantation Proceedings, February 1997, Elsevier

    Fabrizio De Ponti

  108. Adrenergic mechanisms in the control of gastrointestinal motility: From basic science to clinical applications

    Article • Pharmacology & Therapeutics, January 1996, Elsevier

    Fabrizio De Ponti

  109. Tonic modulation of neurotransmitter release in the guinea-pig myenteric plexus: effect of μ and κ opioid receptor blockade and of chronic sympathetic denervation

    Article • Neuroscience Letters, July 1995, Elsevier

    Fabrizio De Ponti

  110. Effect of desipramine-induced blockade of neuronal uptake mechanisms on adrenoceptor-mediated responses in the guinea-pig colon

    Article • Naunyn-Schmiedeberg s Archives of Pharmacology, November 1994, Springer Science + Business Media

    Fabrizio De Ponti

  111. Calcium-channel blockers and gastrointestinal motility: Basic and clinical aspects

    Article • Pharmacology & Therapeutics, January 1993, Elsevier

    Fabrizio De Ponti

  112. Motility of rabbit proximal colon

    Article • Digestive Diseases and Sciences, November 1992, Springer Science + Business Media

    Fabrizio De Ponti

  113. Calcium antagonists and intestinal motility: Inhibition of muscular and nerve-mediated activities

    Article • Pharmacological Research, September 1992, Elsevier

    Fabrizio De Ponti

  114. Control of intestinal motility by different receptor systems

    Article • Pharmacological Research, February 1992, Elsevier

    Fabrizio De Ponti

  115. Intraduodenal absorption of the new UF- heparin salt ITF 1057 in the conscious dog

    Article • Thrombosis Research, June 1991, Elsevier

    Fabrizio De Ponti

  116. Pharmacological activity and safety of trandolapril (RU 44570) in healthy volunteers

    Article • European Journal of Clinical Pharmacology, February 1991, Springer Science + Business Media

    Fabrizio De Ponti

  117. Regulation of intestinal motility by different muscarinic receptor subtypes

    Article • European Journal of Pharmacology, July 1990, Elsevier

    Fabrizio De Ponti

  118. Pharmacokinetics of the total triterpenic fraction of Centella asiatica after single and multiple administrations to healthy volunteers. A new assay for asiatic acid

    Article • Journal of Ethnopharmacology, February 1990, Elsevier

    Fabrizio De Ponti

  119. Effects of a New 1, 4-Dihydropyridine, Lacidipine, on Gastrointestinal Motility and Other Gastrointestinal Functions

    Article • Pharmacology, January 1990, Karger Publishers

    Fabrizio De Ponti

  120. Inhibitory effects of calcium channel blockers on intestinal motility in the dog

    Article • European Journal of Pharmacology, September 1989, Elsevier

    Fabrizio De Ponti

  121. Relaxatory responses of canine proximal stomach to esophageal and duodenal distension

    Article • Digestive Diseases and Sciences, June 1989, Springer Science + Business Media

    Fabrizio De Ponti

  122. Inhibitory Effects of DF 594, a New Antispasmodic Agent, on Intestinal Motility in the Dog

    Article • Pharmacology, January 1989, Karger Publishers

    Fabrizio De Ponti

  123. Recent advances in the physiology and pharmacology of intestinal motility

    Article • Pharmacological Research, January 1989, Elsevier

    Fabrizio De Ponti

  124. Inhibitory action of capsaicin on cholinergic responses induced by GABAA agonists in the guinea-pig ileum

    Article • European Journal of Pharmacology, September 1986, Elsevier

    Fabrizio De Ponti

  125. A re-appraisal of the mode of action of 5-HT in inhibiting GABA-induced cholinergic contractions in the guinea-pig ileum

    Article • European Journal of Pharmacology, August 1986, Elsevier

    Fabrizio De Ponti

  126. Depression by morphine of the excitability of intrinsic inhibitory neurons in the guinea-pig colon

    Article • European Journal of Pharmacology, September 1985, Elsevier

    Fabrizio De Ponti

  127. Subsensitivity of enteric cholinergic neurones to α2-adrenoceptors agonists after chronic sympathetic denervation

    Article • Naunyn-Schmiedeberg s Archives of Pharmacology, May 1985, Springer Science + Business Media

    Fabrizio De Ponti